Recent Announcements

Institute for Clinical and Economic Review Updates Value-Based Price Benchmark for Alirocumab, a PCSK9 Inhibitor for Treatment of High Cholesterol

-- Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, net of rebates and discounts, for alirocumab in patients with a recent acute coronary event: $2,300-$3,400 per year if used to treat all patients who meet trial eligibility criteria, and $4,500-$8,000 per year if used to treat higher-risk patients with LDL cholesterol ≥ 100 mg/dL despite intensive statin therapy --

Read More

Institute for Clinical and Economic Review Final Report: Broader Benefits of Voretigene Neparvovec to Affected Individuals and Society Provide Reasonable Long-Term Value Despite High Price

-- Appraisal committee vote reveals differences in judgments on value given pricing far above traditional cost-effectiveness levels --

--Policy recommendations call attention to the growing stream of treatments for rare disorders that cannot all be priced at similar levels without threatening the financial sustainability of the health system --

Read More